Home Cart Sign in  
Chemical Structure| 871224-64-5 Chemical Structure| 871224-64-5

Structure of Almorexant
CAS No.: 871224-64-5

Chemical Structure| 871224-64-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Almorexant is a potent and competitive dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist with Ki values of 1.3 and 0.17 nM for OX1 and OX2, respectively.

Synonyms: ACT 078573

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Almorexant

CAS No. :871224-64-5
Formula : C29H31F3N2O3
M.W : 512.56
SMILES Code : FC(F)(F)C(C=C1)=CC=C1CC[C@H]2C3=CC(OC)=C(OC)C=C3CCN2[C@H](C4=CC=CC=C4)C(NC)=O
Synonyms :
ACT 078573
MDL No. :MFCD22419385

Safety of Almorexant

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Almorexant

pyroptosis

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Tg2576 mice Human APP transgenic mice Intracerebroventricular injection 13.9 nmole/hr 24 hours Suppressed ISF Aβ levels and abolished the natural diurnal variation of Aβ PMC2789838
Mice Grm2-Cre mice Intraperitoneal injection 30 mg/kg Single dose Almorexant significantly reversed the sleep fragmentation in LHb-TeLC mice, reducing wake time and increasing NREM sleep time, but had no significant effect on REM sleep time. PMC5835141
Sprague-Dawley rats Rats implanted for EEG/EMG recording Oral 100 mg/kg Single dose, observed for 90 minutes To compare the effects of ALM and ZOL on the functional activation of wake-promoting systems at doses equipotent for sleep induction. Results showed that ALM is permissive for the activation of wake-promoting neurons during forced wakefulness, whereas ZOL inhibits this activation. PMC4748439
Wistar rats Accelerating rotating rod (rotarod) and forepaw grip strength tests Oral 30, 100, 300 mg/kg Single administration, testing lasted for 2.5 hours To evaluate the effects of Almorexant alone or in combination with ethanol on motor performance in rats. Results showed that Almorexant alone did not affect rotarod performance or grip strength, and its combination with ethanol did not further reduce performance or grip strength. PMC3055732
BALB/c mice Unpredictable chronic mild stress (UCMS) model Oral 100 mg/kg/day Once daily for 7 weeks To evaluate the effects of Almorexant on UCMS-induced behavioral and physiological changes. Results showed that Almorexant reversed UCMS-induced reductions in weight gain, increased aggression, increased despair behavior, and increased anxiety behavior. Additionally, Almorexant restored UCMS-induced disruption of HPA axis negative feedback regulation. PMC3422486
Rats Post-traumatic stress disorder (PTSD) animal model Intraperitoneal injection 150 mg/kg Single dose, 30 minutes before exposure to predator-scent stress (PSS) To evaluate the effects of Almorexant on behavioral responses following PSS exposure, results showed that rats treated with Almorexant displayed a higher prevalence of the PTSD phenotype. PMC7026175
Mice Narcolepsy model Intraperitoneal injection 30, 100, 300 mg/kg Once every 3 days, lasting 12 hours To evaluate the hypnotic and cataplexy-inducing efficacy of a Hcrt antagonist in an animal model with low Hcrt tone and compare the ALM efficacy profile in the disease model to that produced in wild-type (WT) control animals. ALM exacerbated cataplexy in TG mice and increased nonrapid eye movement sleep with heightened sleep/wake fragmentation in both genotypes. ALM showed greater hypnotic potency in WT mice than in TG mice. The 100 mg/kg dose conferred maximal promotion of cataplexy in TG mice and maximal promotion of REM sleep in WT mice. In TG mice, ALM (30 mg/kg) paradoxically induced a transient increase in active wakefulness. Core body temperature (Tb) decreased after acute Hcrt receptor blockade, but the reduction in Tb that normally accompanies the wake-to-sleep transition was blunted in TG mice. PMC3571748
Mice Wild-type and knockout mice Oral 25, 50, 100, 200, 300 mg/kg Single dose To study the effects of Almorexant on sleep and locomotor activity PMC3490355
Wild-type and prepro-orexin knockout mice Wild-type and prepro-orexin knockout mice Oral 30 and 100 mg/kg Single dose, observed for 6 hours To examine the effects of Almorexant on sleep-wake behavior and cataplexy. Results showed that Almorexant significantly increased NREM and REM sleep in wild-type mice but had no effect in prepro-orexin knockout mice. In the presence of chocolate, Almorexant significantly increased cataplexy episodes. PMC7294412
Mice Kcna1 -null mouse model Intraperitoneal injection 100 mg/kg Once daily for 3 consecutive days To evaluate the effects of Almorexant on sleep and seizures in Kcna1 -null mice. Results showed that Almorexant significantly increased the number and duration of NREM sleep epochs, reduced the latency to REM sleep onset, and decreased the incidence of severe seizures and overall seizure burden. PMC4712395

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.95mL

0.39mL

0.20mL

9.75mL

1.95mL

0.98mL

19.51mL

3.90mL

1.95mL

References

 

Historical Records

Categories